Combination therapy with toripalimab and lenvatinib in metastatic type 2 papillary renal cell carcinoma: a Case Report
This case underscores the potential efficacy and tolerability of toripalimab-lenvatinib combination therapy in metastatic type 2 PRCC. Further clinical trials are warranted to validate this approach.
Authors
- De Zeng (ORCID: https://orcid.org/0000-0002-9141-5505)
- Wende Wang (ORCID: https://orcid.org/0000-0003-2000-3914)
- Minna Chen
- Wenwu Xue
Institutions
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1591489
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00